Yipinhong Pharmaceutical Co Ltd Class A Market Cap ($1.88 Billion)
Market Cap & Net Worth: Yipinhong Pharmaceutical Co Ltd Class A (300723)
Yipinhong Pharmaceutical Co Ltd Class A market cap. Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) has a market capitalization of $1.88 Billion (CN¥12.82 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #6138 globally and #1136 in its home market, demonstrating a -6.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yipinhong Pharmaceutical Co Ltd Class A's stock price CN¥28.39 by its total outstanding shares 451692766 (451.69 Million). Also see 300723 cash generation efficiency for how efficiently the company converts equity into cash flow.
Yipinhong Pharmaceutical Co Ltd Class A Market Cap History (2017–2026)
Yipinhong Pharmaceutical Co Ltd Class A market cap history from 2017 to 2026. Data shows growth from $843.63 Million to $1.88 Billion (14.05% CAGR). Check Yipinhong Pharmaceutical Co Ltd Class A (300723) stock price for real-time trading data and today's change.
Yipinhong Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300723 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.38x
Yipinhong Pharmaceutical Co Ltd Class A's market cap is 2.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $843.63 Million | $1.38 Billion | $156.70 Million | 0.61x | 5.38x |
| 2018 | $629.59 Million | $1.43 Billion | $208.22 Million | 0.44x | 3.02x |
| 2019 | $908.89 Million | $1.64 Billion | $143.69 Million | 0.56x | 6.33x |
| 2020 | $956.84 Million | $1.68 Billion | $225.61 Million | 0.57x | 4.24x |
| 2021 | $1.55 Billion | $2.20 Billion | $306.92 Million | 0.70x | 5.04x |
| 2022 | $1.50 Billion | $2.28 Billion | $290.68 Million | 0.66x | 5.16x |
| 2023 | $1.95 Billion | $2.50 Billion | $184.61 Million | 0.78x | 10.58x |
| 2024 | $1.13 Billion | $1.45 Billion | -$540.04 Million | 0.78x | N/A |
| 2025 | $2.22 Billion | $932.27 Million | -$337.79 Million | 2.38x | N/A |
Competitor Companies of 300723 by Market Capitalization
Companies near Yipinhong Pharmaceutical Co Ltd Class A in the global market cap rankings as of November 4, 2026. Also see Yipinhong Pharmaceutical Co Ltd Class A assets under control for a full breakdown of the balance sheet.
Key companies related to Yipinhong Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Yipinhong Pharmaceutical Co Ltd Class A (2017–2026)
Market capitalization of Yipinhong Pharmaceutical Co Ltd Class A from 2017 to today. Between 2017 and today, Yipinhong Pharmaceutical Co Ltd Class A's market cap moved from $843.63 Million to $ 1.88 Billion, with a yearly change of 14.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.88 Billion | -15.38% |
| 2025 | CN¥2.22 Billion | +96.66% |
| 2024 | CN¥1.13 Billion | -42.27% |
| 2023 | CN¥1.95 Billion | +30.21% |
| 2022 | CN¥1.50 Billion | -3.00% |
| 2021 | CN¥1.55 Billion | +61.63% |
| 2020 | CN¥956.84 Million | +5.28% |
| 2019 | CN¥908.89 Million | +44.36% |
| 2018 | CN¥629.59 Million | -25.37% |
| 2017 | CN¥843.63 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Yipinhong Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.88 Billion USD |
| MoneyControl | $1.88 Billion USD |
| MarketWatch | $1.88 Billion USD |
| marketcap.company | $1.88 Billion USD |
| Reuters | $1.88 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more